Telix’s BiPASS program receives FDA Fast Track as prostate cancer diagnosis moves toward imaging before biopsy. What it means.
How could a shift in prostate cancer diagnosis affect Telix Pharmaceuticals?
Telix’s BiPASS program receives FDA Fast Track as prostate cancer diagnosis moves toward imaging before biopsy. What it means.